Results 1 to 10 of about 3,274,326 (383)

Applications of Single-Cell Omics in Tumor Immunology. [PDF]

open access: greenFront Immunol, 2021
The tumor microenvironment (TME) is an ecosystem that contains various cell types, including cancer cells, immune cells, stromal cells, and many others. In the TME, cancer cells aggressively proliferate, evolve, transmigrate to the circulation system and
Liu J   +7 more
europepmc   +4 more sources

Tumor-derived microparticles in tumor immunology and immunotherapy. [PDF]

open access: hybridEur J Immunol, 2020
Microvesicles or microparticles, a type of cytoplasm membrane‐derived extracellular vesicles, can be released by cancer cells or normal cell types. Alteration of F‐actin cytoskeleton by various signals may lead to the cytoplasm membrane encapsulating ...
Ma J, Zhang H, Tang K, Huang B.
europepmc   +4 more sources

High-content CRISPR screening in tumor immunology [PDF]

open access: yesFrontiers in Immunology, 2022
CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions.
Erin A. Holcomb   +16 more
doaj   +3 more sources

The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. [PDF]

open access: goldFront Immunol, 2020
Circular RNAs (circRNAs) are covalently closed RNA molecules in eukaryotes with features of high stability, tissue-specific and cell-specific expression. According to their biogenesis, circRNAs are mainly classified into five types, i.e. exonic circRNAs (
Fang Z, Jiang C, Li S.
europepmc   +4 more sources

Organoid Models of Tumor Immunology. [PDF]

open access: yesTrends Immunol, 2020
Cellular interactions in the tumor microenvironment (TME) significantly govern cancer progression and drug response. The efficacy of clinical immunotherapies has fostered an exponential interest in the tumor immune microenvironment, which in turn has engendered a pressing need for robust experimental systems modeling patient-specific tumor-immune ...
Yuki K, Cheng N, Nakano M, Kuo CJ.
europepmc   +6 more sources

Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. [PDF]

open access: greenJ Dent Res, 2018
The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general ...
Moskovitz JM, Ferris RL.
europepmc   +4 more sources

In ovo model in cancer research and tumor immunology. [PDF]

open access: yesFront Immunol, 2022
Considering cancer not only as malignant cells on their own but as a complex disease in which tumor cells interact and communicate with their microenvironment has motivated the establishment of clinically relevant 3D models in past years.
Miebach L, Berner J, Bekeschus S.
europepmc   +2 more sources

Epigenetics of Dendritic Cells in Tumor Immunology. [PDF]

open access: yesCancers (Basel), 2022
Simple Summary Dendritic cells (DCs) are an important type of immune cell present in the blood and tissues, capable of detecting potential threats and displaying them to lymphocytes in the lymph nodes, therefore initiating lymphocyte-mediated responses ...
Godoy-Tena G, Ballestar E.
europepmc   +2 more sources

Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy. [PDF]

open access: yesFront Immunol, 2022
Lung cancer is the second most common and the most lethal malignancy worldwide. It is estimated that lung cancer in never smokers (LCINS) accounts for 10-25% of cases, and its incidence is increasing according to recent data, although the reasons remain ...
de Alencar VTL   +4 more
europepmc   +2 more sources

Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. [PDF]

open access: yesCold Spring Harb Perspect Med, 2022
Historically, non-small-cell lung cancer (NSCLC) has been regarded as a nonimmunogenic tumor; however, recent studies have shown that NSCLCs are among the most responsive cancers to monoclonal antibody immune checkpoint inhibitors (ICIs).
Cascone T   +3 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy